Eptinezumab

Drug Profile

Eptinezumab

Alternative Names: ALD-403

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 23 Feb 2017 Alder announces intention to submit BLA to US FDA
  • 05 Dec 2016 Alder Biopharmaceuticals plans a phase III trial for Migraine (Prevention) in USA and Georgia (NCT02985398)
  • 01 Dec 2016 Alder Biopharmaceuticals initiates a phase III trial for Migraine (Prevention) in USA (NCT02985398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top